News 19 and Make-A-Wish Alabama partner up for Wishes Can't Wait telethon
HUNTSVILLE, Ala. (WHNT) — More than 70 children in North Alabama are waiting for Make-A-Wish Alabama to grant their wishes.
That's why News 19 is partnering with Make-A-Wish Alabama to help fulfill these wishes, because Wishes Can't Wait!
The children who are waiting for their wishes to be granted are all living with a critical illness. Some of those children have spent most of their lives in and out of doctors' offices, hospitals and treatments.
Make-A-Wish helps those children live a life outside of their medical complications by offering them a joyful moment amidst an otherwise difficult time. Whether it's meeting a celebrity, asking for a gift, or planning the trip of a lifetime, Make-A-Wish wants to give every child their dream.
Those wishes make a big impact. Last year, Make-A-Wish surveyed over 3,000 wish alumni, wish parents and medical professionals about the impact of granted wishes. Here's what they found:
Nine out of 10 wish kids reported that the wish experience relieved them from traumatic stress
Nine out of 10 wish parents saw their child's emotional well-being improve with a wish
Nine out of 10 medical providers say a wish increased compliance with treatment
Nine out of 10 medical providers observed that the wish experience has a positive impact on a child's physical well-being and overall quality of life
Eight out of 10 wish kids reported that their wish gave them the strength to fight their critical illness
The problem is that wishes are expensive. The average wish costs $10,000, and Make-A-Wish relies on donors to grant every single one. 245 children are waiting throughout Alabama, and 78 of them are in North Alabama. Any of those children could be your neighbors, co-workers' kids, or classmates of your own children.
Anyone can donate, including businesses! We encourage business owners in the area to consider Wake Up for Wishes as part of their philanthropy efforts.
We know our viewers have a heart for service, and you prove it over and over again.
The Wake Up for Wishes telethon is June 11 this year and will run all day! In the weeks leading up, we're introducing you to children right here in North Alabama who are waiting for their wishes to be granted. We do this so you can see firsthand the precious faces your money benefits.
The best part is you know your money is staying right here in the state. 100% of the proceeds go to children in our backyard, fighting these unimaginable medical battles.
We are accepting donations right now! If you'd like to donate online, you can donate here. You can also text WISHES to 44834.
Make-A-Wish Alabama has granted over 1,700 wishes since the chapter's founding in 2012.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
37 minutes ago
- Business Upturn
BrainDefender Research Announces Launch of New Cognitive Support Formula for Adults
Denver, June 06, 2025 (GLOBE NEWSWIRE) — BrainDefender Research today announced the launch of BrainDefender Memory Support Supplement , a new cognitive wellness formula developed to support focus, mental clarity, and memory in adults. Manufactured in a GMP-certified facility in the United States, the product is designed for individuals seeking to maintain healthy cognitive function through natural, plant-based supplementation. The new formula features a combination of Ginkgo Biloba, Bacopa Monnieri, Huperzine-A, Phosphatidylserine, and N-Acetyl-L-Carnitine—ingredients that have each been individually studied for their potential roles in brain function. BrainDefender Research emphasizes that the supplement is intended for use as part of a wellness routine to support cognitive performance and healthy aging. 'Consumer interest in natural brain support has grown significantly in recent years,' said a spokesperson for BrainDefender Research. 'We developed this product to offer adults a well-rounded option for supporting mental clarity, focus, and memory performance using recognizable, research-supported ingredients.' The company recommends consistent daily use over a 90-day period for best results and offers a 60-day refund policy for customer satisfaction. The product is available for purchase in 30-day, 90-day, and 180-day supply options to accommodate individual wellness goals. Availability BrainDefender Memory Support Supplement can be ordered directly through the company's official website and is also offered via the ClickBank platform. Domestic orders are typically delivered within 5–7 business days, while international shipping may take 10–12 business days. About BrainDefender Research BrainDefender Research is a U.S.-based wellness company focused on the development of cognitive support supplements using plant-based ingredients. All products are manufactured in GMP-certified facilities to ensure quality and safety in every batch. Disclaimer These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individuals should consult a licensed healthcare provider before beginning any new supplement routine, especially if taking medications or managing a medical condition. Media Contact Email: [email protected] Phone: (855) 473-4405 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Yahoo
3 hours ago
- Yahoo
BrainDefender Research Announces Launch of New Cognitive Support Formula for Adults
Plant-Based Supplement Includes Five Individual Ingredients Studied for Their Role in Supporting Memory and Focus Denver, June 06, 2025 (GLOBE NEWSWIRE) -- BrainDefender Research today announced the launch of , a new cognitive wellness formula developed to support focus, mental clarity, and memory in adults. Manufactured in a GMP-certified facility in the United States, the product is designed for individuals seeking to maintain healthy cognitive function through natural, plant-based supplementation. The new formula features a combination of Ginkgo Biloba, Bacopa Monnieri, Huperzine-A, Phosphatidylserine, and N-Acetyl-L-Carnitine—ingredients that have each been individually studied for their potential roles in brain function. BrainDefender Research emphasizes that the supplement is intended for use as part of a wellness routine to support cognitive performance and healthy aging. 'Consumer interest in natural brain support has grown significantly in recent years,' said a spokesperson for BrainDefender Research. 'We developed this product to offer adults a well-rounded option for supporting mental clarity, focus, and memory performance using recognizable, research-supported ingredients.' The company recommends consistent daily use over a 90-day period for best results and offers a 60-day refund policy for customer satisfaction. The product is available for purchase in 30-day, 90-day, and 180-day supply options to accommodate individual wellness goals. AvailabilityBrainDefender Memory Support Supplement can be ordered directly through the company's official website and is also offered via the ClickBank platform. Domestic orders are typically delivered within 5–7 business days, while international shipping may take 10–12 business days. About BrainDefender ResearchBrainDefender Research is a U.S.-based wellness company focused on the development of cognitive support supplements using plant-based ingredients. All products are manufactured in GMP-certified facilities to ensure quality and safety in every batch. DisclaimerThese statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individuals should consult a licensed healthcare provider before beginning any new supplement routine, especially if taking medications or managing a medical condition. Media Contact Email: support@ Phone: (855) 473-4405 CONTACT: Email: support@ Phone: (855) 473-4405Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
15 hours ago
- Business Wire
OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma
NEW YORK--(BUSINESS WIRE)-- OS Therapies Inc. (NYSE-A: OSTX) ('OS Therapies' or 'the Company'), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced it has submitted a request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the prevention of metastases in recurrent, fully-resected, lung metastatic pediatric osteosarcoma. RMAT designations are granted to sponsors with regenerative medicine therapies for serious or life-threatening conditions and provide sponsors with various benefits, including eligibility for an accelerated Biologics License Application (BLA) review. OST-HER2 has already received Rare Pediatric Disease Designation (RPDD), Orphan Drug Designation (ODD) and Fast Track Designation (FTD) for osteosarcoma from the U.S. FDA. If OST-HER2 receives a conditional BLA via Accelerated Review prior to September 30, 2026, the Company will become eligible to receive a Priority Review Voucher (PRV) that it intends to immediately sell. The most recent publicly disclosed PRV sale, valued at $155 million, occurred in May 2025. The Company is awaiting feedback by mid-June 2025 from a Type D meeting with FDA regarding the statistical analysis plan to be used in an End of Phase 2 meeting for OST-HER2 in the prevention of metastases in recurrent, fully-resected, lung metastatic pediatric osteosarcoma. Upon receipt of the Type D Meeting feedback, the Company intends to promptly request the End of Phase 2 meeting with FDA in which it will be seek agreement to allow it to begin a rolling BLA submission in the third quarter of 2025. The grant of the RMAT designation in the third quarter of 2025 complements the company's parallel efforts in other major markets, including Europe and the United Kingdom, where the company plans to seek EMA PRIME Designation and Conditional Market Access (CMA) applications. In parallel to regulatory engagement and market access planning for OST-HER2, the Company is preparing for the late stage clinical development of other pipeline candidates. As such, the Company is well positioned for sustained growth across multiple therapeutic modalities. About OS Therapies OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency. The Company has demonstrated positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a BLA to the U.S. FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the U.S. FDA and other risks and uncertainties described in 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in the Company's most recent Annual Report on Form 10-K and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
